Scott L. Letendre
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Scott L. Letendre has a total of 4 co-authors. Here are the top co-authors by number of shared publications:
Edmund V. Capparelli
HIV Neurobehavioral Research Center1 and Pediatric Pharmacology Research Unit,2 University of California, San Diego, California
1 shared publicationJ. Allen McCutchan
HIV Neurobehavioral Research Center1 and Pediatric Pharmacology Research Unit,2 University of California, San Diego, California
1 shared publication- Ronald James Ellis
Department of Neurosciences, University of California San Diego
1 shared publication The HIV NEUROBEHAVIORAL RESEARCH CENTER GROUP
1 shared publication
Latest Publications
- 1 August 2000
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (8) , 2173-2175
Indinavir Population Pharmacokinetics in Plasma and Cerebrospinal Fluid
Plasma and cerebrospinal fluid (CSF) indinavir concentrations were measured by high-performance liquid chromatography. The median concentration in plasma exceeded that in CSF 10-fold. The modeled CSF curve was flat at 155 nM, and the estimated ratio of the areas under the CSF and plasma concentration-time curves was 6%. We conclude that CSF indinavir concentrations are lower than levels in plasma but exceed the clinical 95% inhibitory concentration range.
- 1 August 2000
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 44 (8) , 2173-2175
Indinavir Population Pharmacokinetics in Plasma and Cerebrospinal Fluid
Plasma and cerebrospinal fluid (CSF) indinavir concentrations were measured by high-performance liquid chromatography. The median concentration in plasma exceeded that in CSF 10-fold. The modeled CSF curve was flat at 155 nM, and the estimated ratio of the areas under the CSF and plasma concentration-time curves was 6%. We conclude that CSF indinavir concentrations are lower than levels in plasma but exceed the clinical 95% inhibitory concentration range.